Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter M Dull

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
Obstetrics and Gynecology|March 5, 2016
Maternal Immunization With an Investigational Trivalent Group B Streptococcal Vaccine: A Randomized Controlled TrialGilbert G G Donders, Scott A Halperin, Roland Devlieger, et al.
Vaccine|October 15, 2010
Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of ageScott A Halperin, Anil Gupta, Robert Jeanfreau, et al.
Human Vaccines & Immunotherapeutics|July 2, 2013
Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccineMaria Elena Santolaya, Miguel O'Ryan, María Teresa Valenzuela, et al.
The Pediatric Infectious Disease Journal|March 30, 2013
Seroprevalence and placental transmission of maternal antibodies specific for Neisseria meningitidis Serogroups A, C, Y and W135 and influence of maternal antibodies on the immune response to a primary course of MenACWY-CRM vaccine in the United KingdomGeraldine Blanchard-Rohner, Matthew D Snape, Dominic F Kelly, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 25, 2015
Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 monthsFiona McQuaid, Matthew D Snape, Tessa M John, et al.
The Pediatric Infectious Disease Journal|April 12, 2014
Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of ageFiona McQuaid, Matthew D Snape, Tessa M John, et al.
Lancet (London, England)|January 21, 2012
Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled studyMaría Elena Santolaya, Miguel L O'Ryan, María Teresa Valenzuela, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|September 25, 2013
Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster doseMatthew D Snape, Praveen Saroey, Tessa M John, et al.
The Pediatric Infectious Disease Journal|August 21, 2013
Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trialMatthew D Snape, John Philip, Tessa M John, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 23, 2003
Clinical features that discriminate inhalational anthrax from other acute respiratory illnessesMatthew J Kuehnert, Timothy J Doyle, Holly A Hill, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Obstetrics and Gynecology|March 5, 2016
Maternal Immunization With an Investigational Trivalent Group B Streptococcal Vaccine: A Randomized Controlled TrialGilbert G G Donders, Scott A Halperin, Roland Devlieger, et al.
Vaccine|October 15, 2010
Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of ageScott A Halperin, Anil Gupta, Robert Jeanfreau, et al.
Human Vaccines & Immunotherapeutics|July 2, 2013
Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccineMaria Elena Santolaya, Miguel O'Ryan, María Teresa Valenzuela, et al.
The Pediatric Infectious Disease Journal|March 30, 2013
Seroprevalence and placental transmission of maternal antibodies specific for Neisseria meningitidis Serogroups A, C, Y and W135 and influence of maternal antibodies on the immune response to a primary course of MenACWY-CRM vaccine in the United KingdomGeraldine Blanchard-Rohner, Matthew D Snape, Dominic F Kelly, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 25, 2015
Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 monthsFiona McQuaid, Matthew D Snape, Tessa M John, et al.
The Pediatric Infectious Disease Journal|April 12, 2014
Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of ageFiona McQuaid, Matthew D Snape, Tessa M John, et al.
Lancet (London, England)|January 21, 2012
Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled studyMaría Elena Santolaya, Miguel L O'Ryan, María Teresa Valenzuela, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|September 25, 2013
Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster doseMatthew D Snape, Praveen Saroey, Tessa M John, et al.
The Pediatric Infectious Disease Journal|August 21, 2013
Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trialMatthew D Snape, John Philip, Tessa M John, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 23, 2003
Clinical features that discriminate inhalational anthrax from other acute respiratory illnessesMatthew J Kuehnert, Timothy J Doyle, Holly A Hill, et al.
Pageof 5